

Photodynamic Diagnosis for Upper Urinary Tract Urothelial Cell Carcinomas

Sarfraz Ahmad*

Department of Urology, Ninewells Hospital, University of Dundee, UK

Upper urinary tract urothelial cell carcinomas (UUT-UCCs), account for 5% of all urothelial tumours with transitional cell carcinoma being the most common type [1,2]. Sixty percent UUT-UCCs are invasive at diagnosis thus reflected by poor outcomes [3,4]. Multidetector computed tomographic urography (MDCTU) is currently considered as the gold standard for the investigation of UUT-UCCs [5,6]. For polypoid lesions between 5 and 10 mm the detection rate with MDCTU are fairly accurate with 96% sensitivity and 99% specificity. However, sensitivity drops to 89% for lesions <5 mm and to 40% for <3 mm lesions [7,8]. These small lesions represent either non-invasive superficial tumours or carcinoma *in situ* (CIS) [9]. Endoscopy assessment especially with flexible ureterorenoscopy (FURS), can explore the ureter macroscopically and reach renal cavities in 95% of cases, obtain biopsy and determine tumour grade in 90% of cases with a low false-negative rate [10].

Traditionally, the standard treatment for UUT-UCCs is a radical nephroureterectomy and a bladder cuff removal [2,11]. However, in selected patients, conservative endoscopic ablation with LASER is explored recently and has produced comparable results to that of radical surgery [2,12]. The endoscopic ablation necessitates repeated FURS and depends on accurate localization of malignant lesions [2,11]. However, even direct visualization with conventional white light FURS can miss small flat tumours [2].

The role of Photodynamic diagnosis (PDD) is now well established in the management of bladder tumours, especially for flat tumours and carcinoma *in situ* (CIS) [13-15]. For photosensitization, two pharmacological agents, Hexaminolevulinic acid and 5- Aminolevulinic Acid (5-ALA), have been investigated for bladder tumours [16-20].

Application of PDD for UUT-UCCs is relatively a new exciting innovation. For UUT-UCCs photosensitization of the upper urinary tract urothelium depends on systemic administration of the photodynamic pharmacological agents. One of these agent, 5 - ALA, has been investigated recently and showed promising results in detection of UUT-UCCs [21].

PDD uses fluorescence to localize malignant lesions by selective accumulation of Protoporphyrin IX in the tumour tissues. PDD principle is based on the interaction of a photosensitizing agent such as 5 - ALA, that has a high uptake by tumour cells, and light (photon) with an appropriate wavelength [2,13,14]. The agent absorbs light as high energy per photon and re-emits it with a lower energy per photon, producing a different wavelength [2,13,14], hence enhancing visualization under blue light.

The role of blue light assisted FURS for investigating UUT- UCCs is still in early stages [22]. Few reported series, using 5 - ALA, have shown enhanced detection of UUT-UCCs with PDD [21,23,24]. The sensitivity and specificity of PDD to detect abnormal tissues in upper urinary tract was reported 96% and 100%, respectively [21]. Furthermore, PDD was able to detect more tumours including CIS than with white light alone [21]. In addition to the detection of overt malignant urothelial lesions, urothelial dysplasia also showed higher fluorescence [24]. Appropriate management and prediction of prognosis of the urothelial cancers require a careful endoscopic evaluation of whole urinary tract. PDD for upper tract also allow bladder inspection under blue light and

showed to detect concomitant bladder cancers [24]. Although the PDD for UUT-UCCs is promising but not without side effects, mainly hypotension and facial redness [21,24].

Early diagnosis and detection of occult urothelial lesions is important as these have important implications on disease progression and management decisions. PDD for upper tract is a step forward in enhancing diagnostic accuracy of FURS. Initial result of PDD for UUT-UCCs are quite encouraging showing feasibility and safety of PDD with additional advantages of detecting lesions not visualised with conventional white light endoscopy. This will be more valuable in patients selected for conservative endoscopic ablation of UUT-UCCs, as PDD will allow complete treatment and subsequent reduction in recurrence. Current evidence support potential use of PDD for investigating, treating and for follow up of patients with UUT-UCCs. However, the available data is quite limited, further multicentre trials with a larger cohort of patients are required to evaluate PDD safety and benefits. Additionally, due to lack of long-term follow up in reported series, correlation of PDD of UUT-UCCs with recurrence free and overall survival need to be established.

References

1. Anderson EM, Murphy R, Rennie AT, Cowan NC (2007) Multidetector computed tomography urography (MDCTU) for diagnosing urothelial malignancy. Clin Radiol 62: 324-332.
2. Audenet F, Traxer O, Yates DR, Cussenot O, Rouprêt M (2012) Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU Int 109: 608-613.
3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, et al. (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52: 594-601.
4. Olgac S, Mazumdar M, Dalbagni G, Reuter VE (2004) Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol 28: 1545-1552.
5. Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, Nolte-Ernsting CC, Takahashi S, et al. (2008) CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 18: 4-17.
6. Wang LJ, Wong YC, Chuang CK, Huang CC, Pang ST (2009) Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol 181: 524-531.
7. Roupret M, Yates DR, Comperat E, Cussenot O (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 54 : 1226-1236.

*Corresponding author: Sarfraz Ahmad, Urology SpR and Clinical Research Fellow, (Focused Ultrasound Surgery Foundation), Department of Urology, Ninewells Hospital, University of Dundee, UK, E-mail: drsarfrazrana@hotmail.com

Received December 27, 2012; Accepted December 27, 2012; Published December 29, 2012

Citation: Ahmad S (2013) Photodynamic Diagnosis for Upper Urinary Tract Urothelial Cell Carcinomas. Med Surg Urol 2:e105. doi:10.4172/2168-9857.1000e105

Copyright: © 2013 Ahmad S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

8. Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, et al. (2009) Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. *BJU Int* 104: 1436-1440.
9. Caoili EM, Cohan RH, Inampudi P, Ellis JH, Shah RB, et al. (2005) MDCT urography of upper tract urothelial neoplasms. *AJR Am J Roentgenol* 184: 1873-1881.
10. Tavora F, Fajardo DA, Lee TK, Lotan T, Miller JS, et al. (2009) Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. *Am J Surg Pathol* 33: 1540-1546.
11. Bader MJ, Sroka R, Gratzke C, Seitz M, Weidlich P, et al. (2009) Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. *Eur Urol* 56: 65-71.
12. Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, et al. (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. *Eur Urol* 59: 584-594.
13. Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, et al. (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. *Int J Technol Assess Health Care* 27: 3-10.
14. Jocham D, Stepp H, Waidelich R (2008) Photodynamic diagnosis in urology: state-of-the-art. *Eur Urol* 53: 1138-1148.
15. van der Meijden AP, Sylvester R, Oosterlinck W, Solsona E, Boehle A, et al. (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. *Eur Urol* 48: 363-371.
16. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, et al. (2004) Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. *J Urol* 171: 135-138.
17. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, et al. (2007) A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. *J Urol* 178: 68-73.
18. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, et al. (2007) A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. *J Urol* 178: 62-67.
19. Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, et al. (2001) Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. *Urology* 57: 690-694.
20. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, et al. (1994) Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. *Urology* 44: 836-841.
21. Aboumarzouk O AS, Moseley H, Kata SG (2012) Photodynamic Diagnosis of Upper Urinary Tract Lesions: Diagnostic Accuracy of our Initial Three Years Experience. *Arab Journal of Urology*.
22. Somani BK, Moseley H, Eljamel MS, Nabi G, Kata SG (2010) Photodynamic diagnosis (PDD) for upper urinary tract transitional cell carcinoma (UT-TCC): evolution of a new technique. *Photodiagnosis Photodyn Ther* 7: 39-43.
23. Waidelich R, Hofstetter A, Stepp H, Baumgartner R, Weninger E, et al. (1998) Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. *J Urol* 159: 401-404.
24. Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG (2012) Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit. *BJU Int*.